Spine BioPharma Chronic Back Pain Study

Do you suffer from chronic lower back pain?

Do you suffer from chronic lower back pain sometimes known as degenerative disc disease? Neurovations is currently enrolling in a new study for chronic lower back pain for patients 18 years and older. This study includes a single investigational intradiscal injection that could provide up to 6 months of clinically meaningful symptomatic relief.

Is this study right for me?

This is a Phase 3 clinical trial of the investigational drug SB-01 for the treatment of Lumbar Degenerative Disc Disease. SB-01 is a peptide administered by an injection into the spinal disc. Possible benefits include the reduction of pain-related disability associated with degenerative disc disease. This study involves a total of 7 visits at our site over the course of 12 months and includes a stipend for each visit.

If accepted for this study, you will receive free study-related medical care.

To see if you qualify, call Neurovations at 707-252-9606 or fill out the form below and we will reach out shortly.

Thank you for your inquiry. By filling out this form, you have given permission to be contacted by Neurovations Research via phone, email or text. We will reach out to you shortly!

About Neurovations Research

Dr Grigsby - CEO and Founder of Neurovations
Dr Grigsby | CEO and Founder of Neurovations

Neurovations Research, founded in 2010, is at the forefront of innovation in the field of pain and neuromodulation. CEO and founder Dr. Eric Grigsby has led clinical trials with more than fifty companies, partnering with industry leaders and early-stage companies in medical device (Phase I-IV) and pharmaceutical trials (Phase II-IV), including first-in-man medical device trials, double-blinded and placebo-controlled trials.

What is Degenerative Disc Disease?

Lumbar Degenerative Disc Disease (DDD) is a condition defined as discogenic back pain and related disability with degeneration of a lumbar disc. DDD’s natural disease course is progressive. If left untreated, DDD leads to substantial disability and back pain that prevents the patient from engaging in work and everyday activities. The degree of DDD’s morbidity (pain and related disability) generally coincides with disease progression and disc degeneration.


266 million individuals around the world have Degenerative Disc Disease, or DDD, and its associated Chronic Low Back Pain each year.  DDD of the lumbar, or lower, spine is a significant cause of disability in the world and a tremendous expense to the healthcare system.  It is associated with a variety of clinical symptoms, including, weakness, low back pain and disability of varying levels of severity. There is currently no treatment for the underlying cause of DDD and current approaches are aimed at managing pain through a variety of approaches that include physical therapy, chiropractic care, over the counter medications like non-steroidal anti-inflammatory drugs (NSAIDS) or prescription opioids.  For patients with moderate to severe pain that persists chronically, treatment plans include epidural steroid injections, nerve blocks, radiofrequency ablation or surgical intervention.  Clinical outcomes vary and often do not provide predictable benefit.  Given the substantial costs, pain, and disability associated with DDD, and the current lack of an approved disease-modifying agent, a therapy that could relieve pain and increase function with the potential to mediate the progression of DDD or achieve a regenerative effect could revolutionize the standard of care.

If accepted for this study, you will receive free study-related medical care.

To see if you qualify, call Neurovations at 707-252-9606 or click on the link below to email us.

Neurovations Research

Neurovations Research, headquartered in Napa, Ca is at the forefront of innovation in medical research. We develop evidence, through clinical research and consulting, to improve the efficiency and speed of delivery of medical devices, pharmaceuticals, and biologics to the patient.